It looks like you're new here. If you want to get involved, click one of these buttons!
div>The risk for complications of postnatally acquired varicella in premature infants is unknown. Because the immune systems of premature infants (some of whom might be extremely low birthweight and spend months in neonatal intensive care units) might be compromised, they are considered, on the basis of expert opinion, at high risk for severe varicella; this increased risk is likely continued for as long as these infants remain hospitalized. Patients receiving monthly high-dose (��400?mg/kg) immune globulin UMI 77 intravenous (IGIV) are likely to be protected and probably do not require VariZIG if the most recent dose of IGIV was administered ��3 weeks before exposure . The decision to administer VariZIG depends on three factors: 1) whether the patient lacks evidence of immunity to varicella, 2) whether the exposure is likely to result in infection, and 3) whether the patient is at greater risk for varicella complications than the general population. For high-risk patients who have additional exposures to varicella-zoster virus ��3 weeks after initial VariZIG administration, another dose of VariZIG should be considered. CDC recommends administration of VariZIG as soon as possible after exposure to varicella-zoster virus and within 10 days. Patients without evidence of immunity to varicella who are at http://www.selleckchem.com/ DZNeP mw high risk for severe varicella and complications, who have been exposed to varicella or herpes zoster, and for whom varicella vaccine is contraindicated, should receive VariZIG. Patient groups recommended by CDC to receive VariZIG include the following: Immunocompromised patients without evidence of immunity. Newborn infants whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after). Hospitalized premature infants born at ��28 weeks of gestation whose mothers do not have evidence of immunity to varicella. Hospitalized premature infants born at <28 weeks of gestation or who weigh ��1,000?g at birth, regardless of their mothers' evidence of immunity to varicella. Pregnant women without evidence of immunity. VariZIG is supplied in 125-IU vials and should be administered intramuscularly as directed by the manufacturer. The recommended dose is 125 IU/10?kg of body weight, up to a maximum of 625 IU (five vials). The minimum dose is 62.5 IU (0.5 vial) for patients weighing ��2.0?kg and 125 IU (one vial) for patients weighing 2.1�C10.0?kg . Unchanged from previous recommendations , for patients who become eligible for vaccination, varicella vaccine should be administered ��5 months after VariZIG administration.